CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis
BackgroundCladribine has been introduced as a high-efficacy drug for treating relapsing-remitting multiple sclerosis (RRMS). Initial cohort studies showed early disease activity in the first year after drug initiation. Biomarkers that can predict early disease activity are needed.AimTo estimate cere...
Spremljeno u:
| Glavni autori: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2024-02-01
|
| Serija: | Frontiers in Immunology |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1343892/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
